Related Experiment Videos
Benefit-risk analysis: a proposal using quantitative methods
William L Holden1, Juhaeri Juhaeri, Wanju Dai
1Aventis Pharmaceuticals, Bridgewater, NJ, USA. William.Holden@aventis.com
Pharmacoepidemiology and Drug Safety
|October 16, 2003
Abstract:
This is the first part of a two-article series which will introduce the theory and practice of a proposed set of quantitative methods for benefit-risk analysis. Adjustments to number-needed-to-treat (NNT) analysis and a new method, minimum clinical efficacy (MCE) analysis are presented and critically discussed. The goal of these methods is to condense into a summary metric the benefit-risk profile of a product so that manufacturers, regulators, clinicians and patients can better understand and participate in risk management. A second article will present examples of these methods.